MedTrace Logo

MiniMed™ 670G System China Study for Type I Diabetic

NCT04663295 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2022-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to obtain clinical data in Chinese patients to support product registration of the MiniMed™ 670G system with the National Medical Product Administration (NMPA) in China. The results from the study will be submitted to the NMPA for product registration.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DEVICE

MiniMed™ 670G system

Hybrid closed loop insulin pump with associated CGM and blood glucose meter

Sponsors & Collaborators

  • Medtronic Diabetes

    lead INDUSTRY

Principal Investigators

  • Yiming Mu, MD · Chinese PLA General Hospital

  • Yan Bi, MD · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  • Yongde Peng, MD · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  • Yanbing Li, MD · First Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-06-22
Completion
2021-06-22
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04663295 on ClinicalTrials.gov